NICE have released a clinical audit tool and a costing statement for the treatment of dyspepsia and gastro‑oesophageal reflux disease to be used alongside their guidance documentation:
CG184 Dyspepsia/GORD: costing statement
CG184 Dyspepsia/GORD: clinical audit tools
Showing posts with label treatment. Show all posts
Showing posts with label treatment. Show all posts
Monday, 15 September 2014
Monday, 13 May 2013
Cost effectiveness of the NHS breast screening programme
"... further primary research will be needed for cost effectiveness studies to provide definitive data to inform policy."
Cost effectiveness of the NHS breast screening programme: life table model
PDP Pharoah, B Sewell, D Fitzimmons, HS Bennett, N Pashayan
British Medical Journal, 2013, 346:f2618
Read more here.
Cost effectiveness of the NHS breast screening programme: life table model
PDP Pharoah, B Sewell, D Fitzimmons, HS Bennett, N Pashayan
British Medical Journal, 2013, 346:f2618
Read more here.
Tuesday, 24 January 2012
Paying for "end-of-life" drugs in Australia, Germany, and the United Kingdom
"This issue brief compares U.K., Australian, and German policies on coverage of end-of-life medicines, particularly those that are not curative and offer modest increments in median survival rates."
Paying for "end-of-life" drugs in Australia, Germany, and the United Kingdom: balancing policy, pragmatism, and societal values
Issues in International Health Policy
The Commonwealth Fund
January 2012
Read more here.
Paying for "end-of-life" drugs in Australia, Germany, and the United Kingdom: balancing policy, pragmatism, and societal values
Issues in International Health Policy
The Commonwealth Fund
January 2012
Read more here.
Subscribe to:
Posts (Atom)